Merck Recalls Chemo Drug Over Packaging Issue
Merck is recalling 276,000 bottles of branded chemotherapy drug, Temodar and generic drug, temozolomide, due to cracked child-proof caps. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - August 19, 2015 Category: Pharmaceuticals Source Type: news
Temodar Bottles Recalled Due to Cracks in Kid-Proof CapsTemodar Bottles Recalled Due to Cracks in Kid-Proof Caps
Consumers are to immediately inspect bottles of Temodar capsules and generic temozolomide capsules for cracked caps; the company is recalling all bottles found to have cracked caps. News Alerts (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 18, 2015 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news
Merck Recalls TEMODAR® and Temozolomide Bottles with Cracked Caps Due to Failure to Meet Child–Resistant Closure Requirement
Dateline City:
KENILWORTH, N.J.
Patients Should Visually Examine Bottle Caps for Cracks and if Cracks are Found, Ensure the Bottles are Stored Out of the Reach of Children
Replacement Caps for Patients Are Available
Medication Within the Bottles Is Not Affected; Patients May Continue to Take Their Medicine as Prescribed
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, in
conjunction with the...
Source: Merck.com - Product News - August 18, 2015 Category: Drugs & Pharmacology Tags: Oncology Newsroom Prescription Medicine News Corporate News Latest News Source Type: news
MD Anderson study shows why some brain cancers resist treatment
(University of Texas M. D. Anderson Cancer Center) Scientists at The University of Texas MD Anderson Cancer Center may have discovered why some brain cancer patients develop resistance to standard treatments including radiation and the chemotherapy agent temozolomide. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 2, 2015 Category: Cancer & Oncology Source Type: news
MD Anderson Study Shows Why Some Brain Cancers Resist Treatment
Scientists at The University of Texas MD Anderson Cancer Center
may have discovered why some brain cancer patients develop resistance
to standard treatments including radiation and the chemotherapy agent
temozolomide. (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - March 2, 2015 Category: Cancer & Oncology Source Type: news
No Benefit from Dose-Dense Chemo in Glioblastoma
(MedPage Today) -- Intensified chemoradiation with temozolomide for newly diagnosed glioblastoma failed to improve survival or slow disease progression, according to results of a randomized trial. (Source: MedPage Today Psychiatry)
Source: MedPage Today Psychiatry - October 13, 2013 Category: Psychiatry Source Type: news
Migration capacity of human umbilical cord mesenchymal stem cells towards glioma in vivo
Glioblastoma is the most common ma-lignant primary brain tumor in adults. The aggressive growth manner, characterized by marked angiogenesis and extensive tumor cell invasion into normal brain parenchyma with frequent formation of tumor microsatellites at distal sites, makes eradication impossible even after extensive microsurgical resection combined with current standard chemoradiation and adjuvant temozolomide. Thus, novel therapeutic strategies must to be investigated for the development of a more effective treatment strategy... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - September 13, 2013 Category: Consumer Health News Tags: Stem Cell Research Source Type: news
Migration capacity of human umbilical cord mesenchymal stem cells towards glioma in vivo
(Neural Regeneration Research) Glioblastoma is the most common malignant primary brain tumor in adults. The aggressive growth manner, characterized by marked angiogenesis and extensive tumor cell invasion into normal brain parenchyma with frequent formation of tumor microsatellites at distal sites, makes eradication impossible even after extensive microsurgical resection combined with current standard chemoradiation and adjuvant temozolomide. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 10, 2013 Category: Global & Universal Source Type: news
Researchers Aiming To Suppress Therapy Resistance In Brain Cancer
Gliomas are malignant brain tumors that arise from glial cells called astrocytes, found in the central nervous system. "In treating malignant gliomas, we currently combine radiotherapy with the anticancer drug temozolomide. However, in some patients, tumors rapidly become resistant to both treatment methods," says neurooncologist Professor Dr. Michael Platten, who leads a cooperation unit of the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) and the Department of Neurooncology of Heidelberg University Hospital... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - June 29, 2013 Category: Consumer Health News Tags: Cancer / Oncology Source Type: news
Virus Combination Effective Against Deadly Brain Tumor, Moffitt Cancer Center Study Shows
A combination of the myxoma virus and the immune suppressant rapamycin can kill glioblastoma multiforme, the most common and deadliest malignant brain tumor, according to Moffitt Cancer Center research. Peter A. Forsyth, M.D., of Moffitt's Neuro-Oncology Program, says the combination has been shown to infect and kill both brain cancer stem cells and differentiated compartments of glioblastoma multiforme. The finding means that barriers to treating the disease, such as resistance to the drug temozolomide, may be overcome... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - June 24, 2013 Category: Consumer Health News Tags: Cancer / Oncology Source Type: news
Roche's Avastin approved in Japan for treatment of the most aggressive form of brain cancer
Roche today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Avastin (bevacizumab) for the treatment of malignant glioma, including newly diagnosed glioblastoma (GBM) in combination with radiotherapy and temozolomide chemotherapy, and as monotherapy for treatment of recurrent GBM and certain other types of high grade glioma following prior therapy. (Source: Roche Investor Update)
Source: Roche Investor Update - June 17, 2013 Category: Pharmaceuticals Source Type: news
Roche's Avastin approved in Japan for treatment of the most aggressive form of brain cancer
Roche today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Avastin (bevacizumab) for the treatment of malignant glioma, including newly diagnosed glioblastoma (GBM) in combination with radiotherapy and temozolomide chemotherapy, and as monotherapy for treatment of recurrent GBM and certain other types of high grade glioma following prior therapy. (Source: Roche Media News)
Source: Roche Media News - June 17, 2013 Category: Pharmaceuticals Source Type: news
Identifying Glioblastoma Patients Most Likely To Benefit From Bevacizumab
This study is associated with RTOG 0825, a large multi-center Phase III trial that evaluated the addition of bevacizumab to standard chemoradiation and maintenance temozolomide in treating newly diagnosed glioblastoma... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - June 4, 2013 Category: Consumer Health News Tags: Cancer / Oncology Source Type: news
Roche announces final phase III study results of Avastin plus radiotherapy and chemotherapy in people with an aggressive form of brain cancer
Roche today announced final results from the phase III AVAglio study in people with newly diagnosed glioblastoma, the most common and aggressive form of primary brain cancer. Final results confirmed people who received Avastin (bevacizumab) plus radiotherapy and temozolomide chemotherapy benefited from a significant improvement in progression-free survival (PFS) compared to those who received placebo plus radiotherapy and temozolomide chemotherapy. Overall survival (OS) was not significantly improved in the study. (Source: Roche Investor Update)
Source: Roche Investor Update - June 1, 2013 Category: Pharmaceuticals Source Type: news
Roche announces final phase III study results of Avastin plus radiotherapy and chemotherapy in people with an aggressive form of brain cancer
Roche today announced final results from the phase III AVAglio study in people with newly diagnosed glioblastoma, the most common and aggressive form of primary brain cancer. Final results confirmed people who received Avastin (bevacizumab) plus radiotherapy and temozolomide chemotherapy benefited from a significant improvement in progression-free survival (PFS) compared to those who received placebo plus radiotherapy and temozolomide chemotherapy. (Source: Roche Media News)
Source: Roche Media News - June 1, 2013 Category: Pharmaceuticals Source Type: news
